Moorfields AMD Dataset 002

The AMD Dataset encompasses all patients who have received at least one injection of either Lucentis (ranibizumab) or Eylea (aflibercept) to treat age-related macular degeneration (AMD) at Moorfields Eye Hospital - a leading provider of eye health services in the UK and a world-class centre of excellence for ophthalmic research and education.

These therapies began at Moorfields in 2007, however, the dataset will include any imaging or clinical metadata that is available for these patients prior to that time (for example in patients who were initially monitored for the early or intermediate forms of this disease prior to receiving treatment). Also of note, this dataset will include data from both eyes in each case - for example, it will include data from fellow eyes that are not receiving injections. For these reasons, the dataset will include longitudinal data from a mixture of eyes with both “dry” and “wet” AMD.

Clinical metadata includes information regarding:
- patient demographics
- visual acuities (predominantly measured with Early Treatment Diabetic Retinopathy Study (ETDRS) charts)
- diabetic retinopathy grading
- intravitreal therapies and ocular surgeries

Additional information is provided in the ‘technical details’ tab.

The AMD dataset includes eye imaging modalities, such as:
- Optical coherence tomography (CSO, Heidelberg, Optos, Topcon, Zeiss)
- Colour fundus photographs (Topcon, Zeiss)
- Ultra-wide field photographs (Optos, Zeiss)
- Iris photographs (CSO, Zeiss)
- Keratoscope topography (CSO)
- Infrared photographs (Heidelberg, Topcon, Zeiss)
- Fluorescein angiography (Heidelberg, Optos, Topcon, Zeiss)
- Indocyanine green angiography (Heidelberg, Optos, Topcon)
- Fundus autofluorescence (Heidelberg, Optos, Zeiss)

Imaging data from CSO is subject to additional approvals.

As of July 2024, the dataset consisted of 12,641 eyes receiving Lucentis or Eylea for AMD, 220,219 injection episodes, and 2,943,338 ophthalmic images. This is the largest single centre database from patients with AMD and covers more than a decade of follow-up for these patients.